Envoy Medical, Inc. filings document a hearing-health company with Class A common stock and redeemable warrants listed on Nasdaq. Its regulatory record covers operating results, financial-condition updates, registration statements for securities offerings, warrant and pre-funded warrant structures, and disclosures related to its status as an emerging growth company.
Company filings also include proxy materials for director elections, auditor ratification, executive compensation, equity incentive and employee stock purchase plan amendments, and Nasdaq share-issuance approvals. Form 8-K disclosures address material agreements, auditor changes, compensatory arrangements, Nasdaq listing compliance, and risk-related matters such as going-concern language in audit reports.
Alta Partners LLC filed a Schedule 13G reporting beneficial ownership of 1,944,139 shares of Envoy Medical, Inc. Class A common stock (shares issuable upon exercise of warrants), representing 8.25% of the class. Alta Partners reports sole voting and dispositive power over these shares and certifies the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Envoy Medical (NASDAQ:COCH) announced the appointment of Robert Potashnick as Interim Chief Financial Officer, effective June 23, 2025. Potashnick, 45, will serve as the company's principal financial officer and principal accounting officer through his consulting entity Oasis Business Consulting LLC. He brings significant experience from previous CFO roles at Flutterbee Education Group and FOXO Technologies, along with positions at UnitedHealth Group and PricewaterhouseCoopers LLP. The appointment is structured through a Consulting Agreement on a fractional consultant basis.